Tag: Bharat Biotech

Human trials of India’s first indigenous experimental vaccine against COVID-19, COVAXIN, developed by Bharat Biotech is set to begin across India in July........................

The Coalition for Epidemic Preparedness Innovations (CEPI) will provide consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) with up to US$14.1 million for vaccine manufacturing and clinical development of a two-dose live-inactivated vaccine (BBV87) against Chikungunya..............

CSIR through its NMITLI program approves a multi institutional project to develop human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in patients. The project will be implemented by National Centre for Cell Science (NCCS), IIT-Indore and PredOmix Technologies with Bharat Biotech International, as the commercialization partner...........................

Earlier marketed under the trade name Rabipur®, this vaccine is presently manufactured using the same technology at the same site..................

Collaboration seeks to accelerate the development, licensure, manufacture and supply of an affordable, next-generation Cholera vaccine to support access in low and middle-income countries.................

The Ankleshwar, Gujarat based Chiron Behring Vaccines which is a part of GlaxoSmithKline Asia will be acquired by Bharat Biotech in an all cash transaction, subject to a number of closing conditions which both the parties intend to complete in the coming weeks................

Launched in 2015 by the Prime Minister of India, Narendra Modi ROTAVAC vaccine was introduced into the Universal Immunization Program in India during 2016, with initial implementation in 9 states with more States in the pipeline.............

The Chairman of Bharat Biotech, Dr Krishna Ella in his remarks at the 6th Foundation Day event of the BIRAC at New Delhi, mentioned that the Indian biotech sector must create its own indigenous model for innovation that would cater to its needs and that of the world............

Mentioned Dr Krishna Ella, Chairman, Bharat Biotech in an exclusive freewheeling interaction with the Biovoice News. While Dr Ella believes that the vaccine industry has arrived, he wants the government to ease the cumbersome processes and support the indigenous innovations..............

ROTAVAC has been under development since the year 2000 necessitating investments of around USD 200 million towards product development and dedicated manufacturing infrastructure. The WHO approval will help in making it accessible and affordable.......